COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity

Chronic lymphocytic leukaemia (CLL) is associated with immunocompromise and high risk of severe COVID-19 disease and mortality. Monoclonal B-cell lymphocytosis (MBL) patients also have immune impairment. We evaluated humoural and cellular immune responses in 181 patients with CLL (160) and MBL (21) to correlate failed seroconversion [<50 AU/ml SARS-CoV-2 II IgG assay, antibody to spike protein; Abbott Diagnostics)] following each of two vaccine doses with clinical and laboratory parameters. Following first and second doses, 79.2% then 45% of CLL, and 50% then 9.5% of MBL patients respectively remained seronegative. There was significant association between post dose two antibody level with pre-vaccination reduced IgM (p < 0.0001), IgG2 (p < 0.035), and IgG3 (p < 0.046), and CLL therapy within 12 months (p < 0.001) in univariate analysis. By multivariate analysis, reduced IgM (p < 0.0002) and active therapy (p < 0.0002) retained significance. Anti-spike protein levels varied widely and were lower in CLL than MBL patients, and both lower than in normal donors. Neutralisation activity showed anti-spike levels <1000 AU/ml were usually negative for both an early viral Glade and the contemporary Delta variant and 72.9% of CLI, and 53.3% of MBI, failed to reach levels >= 1000 AU/ml. In a representative sample, similar to 80% had normal T-cell responses. Failed seroconversion occurred in 36.6% of treatment-naive patients, in 78.1% on therapy, and in 85.7% on ibrutinib.

Automated summary

Chronic lymphocytic leukaemia (CLL) and monoclonal B-cell lymphocytosis (MBL) patients have poor immune response to COVID-19 vaccines, with most of them failing to produce sufficient antibody levels. The patients' treatment status and reduced immune function are associated with vaccine immunization failure.